New England Journal of Medicine· 2015Q1· Clinical trial
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- 5,913citations
- Q1SCImago
- 2015year
Short summary
Nivolumab significantly improved overall survival by a median of 5.4 months compared to everolimus in patients with advanced renal-cell carcinoma who had received prior treatment.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine